Strategies to Detect and Mitigate Bias and Overfitting in Clinical Machine Learning Models

Understanding Bias in Clinical ML Models

Bias in machine learning refers to systematic errors in model predictions caused by underlying assumptions, poor data representation, or process gaps. In clinical trials, this can lead to unsafe or inequitable decisions affecting patient selection, dose adjustments, or protocol deviations.

Common sources of bias in clinical ML models include:

• 📝 Demographic imbalance: Overrepresentation of one ethnicity or age group
• 📉 Data drift: Historical trial data not reflecting present-day practices
• 📊 Labeling inconsistency: Different investigators labeling data differently across studies
• ⚠️ Selection bias: Trial participants not being representative of target populations

Bias can distort endpoints and increase trial risk. Sponsors must conduct fairness audits and subgroup performance analyses to quantify and address model bias. The FDA encourages proactive assessments of demographic performance during model validation.

Overfitting and Its Impact on Model Reliability

Overfitting occurs when a model learns noise instead of signal, performing well on training data but poorly on unseen data. This is particularly dangerous in regulated environments like clinical research, where generalizability is crucial.

Symptoms of overfitting include:

• 🔎 High training accuracy but low test accuracy
• 📊 Drastic accuracy drops in cross-validation
• ⚠️ Unstable predictions for minor changes in input data

In GxP-regulated environments, overfitting invalidates model reproducibility and robustness. Regulatory reviewers may flag overfitted models as unreliable or unsafe for decision-making.

Preventing Overfitting: Best Practices

Pharma data scientists must adopt preventive strategies to ensure robust, scalable models:

• ✅ Use stratified train-test splits (e.g., 80/20 or 70/30) with data shuffling
• 📈 Apply k-fold cross-validation (usually 5 or 10 folds) for model evaluation
• 📝 Regularization techniques such as L1/L2 for penalizing complexity
• 📊 Early stopping in iterative algorithms like neural networks
• 📓 Train on larger datasets or use data augmentation for rare event modeling

One can reference PharmaValidation.in for detailed templates on validation protocols covering overfitting prevention checkpoints.

Bias Mitigation Techniques in Clinical ML

Mitigating bias in clinical models requires a combination of preprocessing, in-processing, and post-processing techniques:

• 📦 Re-sampling techniques like SMOTE to balance minority groups
• 🔧 Feature selection audits to avoid proxies for race, gender, etc.
• 📏 Fairness constraints integrated into model training (e.g., equal opportunity)
• 💼 Bias dashboards that display subgroup metrics across age, sex, ethnicity

It is critical to document all bias mitigation decisions. For regulatory acceptance, models must show that fairness efforts are measurable, traceable, and reproducible. EMA’s AI reflection paper emphasizes ethical responsibility in training algorithms that impact patient care.

Regulatory Expectations for Bias and Overfitting

While regulatory authorities have yet to release formal AI validation guidelines, several draft and reflection papers set the tone:

• 📄 FDA’s Good Machine Learning Practice (GMLP) emphasizes transparency, performance metrics, and monitoring
• 📄 EMA’s AI Reflection Paper advocates for explainability and equitable performance across demographics
• 📄 ICH Q9 (R1) supports Quality Risk Management applicable to AI bias

Validation reports submitted to inspectors should include a summary of bias testing, overfitting assessments, and justification of risk controls. Use of tools like LIME and SHAP for explainability should be documented with visual outputs.

Case Study: Bias Detection in Oncology Trial Risk Stratification

A sponsor developed a ML model to stratify oncology patients for early progression risk. Initial results showed high accuracy (AUC 0.88), but performance dropped in Asian and Latin American subgroups. Upon investigation:

• 📈 The training set had 78% Caucasian patients, leading to demographic skew
• 📝 Inclusion of regional biomarker data helped improve minority group accuracy
• ✅ Updated model achieved 0.84 AUC consistently across all major subgroups

Learnings from this case reinforced the need for balanced training data and subgroup performance evaluation early in the ML lifecycle. The revised model was submitted along with a ClinicalStudies.in-style validation report and passed regulatory review without objections.

Continuous Monitoring and Drift Detection

Bias and overfitting are not just one-time concerns; they evolve with data and trial protocol changes. ML models should undergo continuous monitoring in production using:

• 📶 Drift detection algorithms to detect shifts in feature distributions
• 📄 Scheduled periodic retraining based on monitored performance
• 📑 Post-market surveillance for models used in decision support systems

Model lifecycle governance must be defined clearly in SOPs, ensuring that monitoring, alerts, and change requests are compliant with audit requirements.

Conclusion

Bias and overfitting pose serious threats to the safety, equity, and reliability of ML models in clinical trials. Addressing them is not optional—it is a regulatory and ethical mandate. Data scientists, sponsors, and QA units must collaborate to build robust frameworks encompassing detection, mitigation, documentation, and continuous improvement. By embedding fairness and generalizability at every lifecycle stage, clinical AI can be both powerful and compliant.

References:

• FDA Good Machine Learning Practice
• EMA AI Reflection Paper
• ICH Quality Guidelines
• PharmaValidation.in
• ClinicalStudies.in

What a Biostatistician Does Every Day in Clinical Trials

1. Understanding the Role of a Biostatistician in Clinical Trials

Biostatisticians play a pivotal role in the success of clinical trials. Their job goes far beyond analyzing data — they help design the study, define the endpoints, manage randomization, write the Statistical Analysis Plan (SAP), and oversee statistical programming and validation. A clinical biostatistician ensures that the data generated from trials are scientifically sound, statistically valid, and compliant with regulatory expectations like those outlined in ICH E9.

Whether working in a pharma company, Contract Research Organization (CRO), or as part of an academic research institute, their work touches nearly every phase of the clinical lifecycle — from protocol development to submission dossiers.

2. Pre-Trial Responsibilities: Protocol Review and SAP Drafting

Each day may begin with reviewing the study protocol. The biostatistician ensures the study design aligns with the intended endpoints. They focus on:

• ✅ Reviewing inclusion/exclusion criteria to ensure measurable outcomes
• ✅ Evaluating the proposed sample size calculation based on power analysis
• ✅ Drafting or reviewing the Statistical Analysis Plan (SAP)

The SAP is a critical document that lays out how statistical analysis will be performed. It defines primary and secondary endpoints, analysis populations (e.g., ITT, PP), missing data handling, and statistical methods like ANCOVA, logistic regression, or survival analysis.

According to PharmaGMP.in, SAPs should be finalized before database lock and aligned with the protocol and CRF design.

3. Randomization Schedules and Blinding

Biostatisticians are also responsible for generating and maintaining randomization schedules. These schedules define how subjects are assigned to treatment arms, using methods such as:

• ✅ Simple randomization
• ✅ Block randomization
• ✅ Stratified randomization

In blinded studies, the biostatistician must coordinate with unblinded teams to maintain trial integrity. Tools such as SAS macros or validated randomization software are often used to generate these lists securely, and output is shared with the IWRS vendor or the designated unblinded statistician.

4. Data Review and Ongoing Monitoring Support

During the conduct phase, the biostatistician regularly reviews data listings, tables, and summaries generated by the programming team. They also support:

• ✅ Data Monitoring Committee (DMC) meetings
• ✅ Interim analyses (IA)
• ✅ Safety signal detection

They may work with medical monitors and data managers to review protocol deviations or outliers. If a study has an interim analysis, the biostatistician ensures the statistical code and simulations are finalized and that the IA results do not compromise the blinding or introduce bias.

5. Statistical Programming and Analysis Execution

Biostatisticians either perform or closely supervise statistical programming. Commonly used tools include SAS, R, and occasionally Python. Typical tasks include:

• ✅ Developing statistical analysis datasets (ADaM)
• ✅ Executing tables, listings, and figures (TLFs)
• ✅ Validating code written by statistical programmers

For example, a biostatistician may run a repeated-measures ANCOVA for a chronic pain trial where scores are recorded weekly. Using SAS PROC MIXED or PROC GLM, they execute the model and interpret estimates, confidence intervals, and interaction terms.

All output must undergo rigorous QC before being included in the Clinical Study Report (CSR).

6. Regulatory Submission Preparation and Review

As the trial concludes, the biostatistician plays a central role in preparing regulatory submissions. This includes:

• ✅ Providing statistical inputs to the CSR
• ✅ Preparing integrated summaries for FDA or EMA submissions
• ✅ Reviewing and responding to Health Authority queries

In one example, during an NDA submission for a diabetes drug, the biostatistician prepared an Integrated Summary of Efficacy (ISE) and an Integrated Summary of Safety (ISS) in CDISC format. These were mapped to FDA requirements and submitted through eCTD format, following FDA Study Data Standards.

7. Cross-Functional Collaboration and Communication

A significant portion of a biostatistician’s day involves communicating results and decisions to various stakeholders. This includes:

• ✅ Presenting to clinical teams and medical directors
• ✅ Collaborating with programmers and data managers
• ✅ Participating in protocol, SAP, and CSR review meetings

Effective communication ensures that the trial’s objectives are met and that interpretations are statistically sound and clinically meaningful. Biostatisticians are often the bridge between raw numbers and actionable conclusions.

8. Continuous Learning and Process Improvement

Given the evolving regulatory landscape and statistical innovations, biostatisticians must keep themselves updated. Their ongoing activities may include:

• ✅ Attending workshops on Bayesian methods or adaptive designs
• ✅ Learning new tools like R Shiny for interactive visualizations
• ✅ Participating in internal process improvement teams

Continuous development ensures compliance with the latest ICH and GCP requirements while improving trial efficiency.

9. Conclusion

The daily work of a clinical trial biostatistician is complex, multi-faceted, and mission-critical. From designing protocols to delivering regulatory-ready data, biostatisticians ensure the scientific credibility of every result. A well-trained statistician is both a guardian of data integrity and a key strategist in trial success.

References:

• PharmaValidation: GxP Templates for Biostatistics and Programming
• ICH E9 Statistical Principles
• FDA Drug Development Tools